Potential contributing etiologies of breakthrough VTE include subtherapeutic anticoagulation (often attributed to suboptimal adherence), antiphospholipid syndrome, established myeloproliferative neoplasm, JAK2 V617F mutation in the absence of an established myeloproliferative neoplasm, and cancer. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.